title: Effect of levosimendan on erythrocyte deformability during myocardial ischaemia-reperfusion injury.
abstract: Diabetes mellitus (DM) is a chronic metabolic disorder accompanied by an increase in oxidative stress. Ischaemia-reperfusion (IR) injury is a cascade of events initiated by tissue ischaemia. The cellular damage produced by reperfusion leads to an active inﬂammatory response. Erythrocyte deformability and plasma viscosity are of crucial importance for the perfusion of tissues and organs. The aim of this study was to evaluate the effect of levosimendan on erythrocyte deformability during IR myocardial injury in diabetic rats.
  
  
  METHODS
  Twenty-four Wistar albino rats were included in the study after streptozocin (55 mg/kg) treatment for 4 weeks to observe the existence of diabetes. The animals were randomly assigned to one of four experimental groups. In Group C and DC (sham-control group), the coronary artery was not occluded or reperfused in the control rats. Myocardial IR was induced by ligation of the left anterior descending coronary artery for 30 min, followed by 2 h of reperfusion in the diabetes-IR (DIR) and diabetes-IR-levosimendan (DIRL) group. Deformability measurements were performed in erythrocyte suspensions containing Htc 5 % in a phosphate-buffered saline (PBS) buffer.
  
  
  RESULTS
  The deformability index was significantly increased in the diabetic rats. It was similar in Group DC and DIRL It was significantly increased in the DIR group compared to Group C, DIRL and DC. The relative resistance was increased in the IR models.
  
  
  CONCLUSIONS
  Erythrocyte deformability was decreased in rats with diabetes and IR injury. This injury might lead to further problems in microcirculation. Levosimendan may be useful in enhancing the adverse effects of this type of injury (Fig. 2, Ref. 41).
  
  
  BACKGROUND
  erythrocyte deformability, myocardial ischaemia reperfusion, experimental diabetes, levosimendan, rat.
authors: M
authors: M
authors: Arslan
authors: F M
authors: FM
authors: Comu
authors: M
authors: M
authors: Alkan
authors: H A
authors: HA
authors: Kiraz
authors: G
authors: G
authors: Kip
authors: A
authors: A
authors: Ozer
authors: V
authors: V
authors: Sivgin
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000150:complications; D004195:Disease Models, Animal; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006835:Hydrazones / Q000494:pharmacology*; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D011724:Pyridazines / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000097:blood; D000077464:Simendan; D013311:Streptozocin
chemical_list: D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D013311:Streptozocin